Stay updated on Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page has removed a citation regarding a phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma, which included an erratum reference.
    Difference
    0.3%
    Check dated 2025-05-22T03:43:19.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:24:51.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to include new information about a clinical trial for metastatic melanoma, specifically mentioning the combination therapy involving Nivolumab and a peptide vaccine. Additionally, the revision number has been updated to v2.15.0.
    Difference
    40%
    Check dated 2025-04-16T10:55:45.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 20, 2025.
    Difference
    0.5%
    Check dated 2025-04-09T05:23:30.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:30:40.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    The web page has been updated with new clinical trial results, including specific metrics such as the number of participants with adverse events and detailed definitions of progression-free survival and overall survival. Additionally, important dates for results reporting have been added.
    Difference
    21%
    Check dated 2025-03-03T22:48:07.000Z thumbnail image

Stay in the know with updates to Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.